hjurp peptides and vaccines including them. The present invention relates to isolated peptides derived from sequence id: 50 and fragments thereof which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy. , more particularly cancer vaccines. The peptides of the invention encompass the above-mentioned amino acid sequences and modified versions thereof, in which one, two or more substituted, deleted, added or inserted amino acid sequences produced such modified versions retain the ability to induce cytotoxic T cells from the original sequence. furthermore, nucleic acids encoding any of the above-mentioned peptides are provided as well as pharmaceutical agents, substances and / or compositions that include or incorporate any of the above-mentioned peptides or nucleic acids. The peptides, nucleic acids, agents, substances and pharmaceutical compositions of this invention find particular utility in the treatment of cancers and tumors, including for example aml, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, cml, colorectal cancer, cancer. of esophagus, diffuse gastric cancer, liver cancer, nsclc, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, sclc, soft tissue tumor and testicular tumor.peptídeos hjurp e vacinas que incluem os mesmos. a presenten invenção refere-se a peptídeos isolados derivados de seq id no: 50 e seus fragmentos que ligam-se a um antígeno hla e induzem linfócitos t citotóxicoas (ctl) e, assim sendo, são apropriados para uso no contexto de imunoterapia de câncer, mais particularmente vacinas de câncer. os peptídes da invenção englobam as sequências de aminoácidos supramencionadas e suas versões modificadas, nas quais uma, duas ou várias sequências de aminoácidos substituídas, deletadas, adicionadas ou inseridas, produziram essas versões modificadas, retêm a capacidade de induzir células t citotóxicas
